Loading ...

Inducing Remission in Type 1 Diabetes With Alefacept

(

T1DAL

)

ITN Protocol #:

ITN045AI

Branded Name:

T1DAL

ClinicalTrials.Gov ID:

Treatment Protocol #:

Alefacept

Therapeutic Area:

Type 1 Diabetes

Current Status:

Complete

ITN Website Clinical Trial Recruiting Site Document Portal Location Study on ITN TrialShare

Summary:

Inducing Remission in New Onset Type 1 Diabetes Mellitus With Alefacept

Clinical Operations Manager

ITN Clinical Trial Physician

NIAID Project Manager

Rho Data Manager

Rho Scientist

Study Personnel:

Protocol Chair

Mark Rigby, MD PhD FAAP FCCM mrigby@iupui.edu

Work:

(317) 274-4145

Protocol Chair

Carol Soppe csoppe@immunetolerance.org

Work:

415-353-4879

Protocol Chair

Srinath Sanda, MD ssanda@immunetolerance.org

Work:

415-353-4414

Protocol Chair

Peggy Fitzgibbon peggy.fitzgibbon@nih.gov

Work:

240-627-3505

Protocol Chair

LaSonia Morgan LaSonia_Morgan@rhoworld.com

Work:

919-595-6379

Protocol Chair

Ashley Pinckney ashley_pinckney@rhoworld.com

Work:

919-595-6271

Admin Links

Shortcuts

ITN Documents

Links